» Articles » PMID: 24688023

CTLA-4 is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells

Overview
Journal J Immunol
Date 2014 Apr 2
PMID 24688023
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

NK cells express an array of activating and inhibitory receptors that determine NK cell responses upon triggering by cognate ligands. Although activating NK cell receptors recognize mainly ligands expressed by stressed, virus-infected, or transformed cells, most inhibitory receptors engage MHC class I, preventing NK cell activation in response to healthy cells. In this study, we provide insight into the regulation and function of additional receptors involved in mouse NK cell responses: CTLA-4 and CD28. CTLA-4 and CD28 engage the same ligands, B7-1 and B7-2, which are primarily expressed by APCs, such as dendritic cells. Our data demonstrate that activation of mouse NK cells with IL-2 induces the expression of CTLA-4 and upregulates CD28. CTLA-4 expression in IL-2-expanded NK cells was further up- or downregulated by IL-12 or TGF-β, respectively. Using gene-deficient NK cells, we show that CD28 induces, and CTLA-4 inhibits, IFN-γ release by NK cells upon engagement by the recombinant ligand, B7-1, or upon coculture with mature dendritic cells. Notably, we show that mouse NK cells infiltrating solid tumors express CD28 and CTLA-4 and respond to stimulation with recombinant B7-1, suggesting that the NK cell responses mediated by the CD28/CTLA-4:B7-1/B7-2 system could be of importance during malignant disease. Accordingly, our study might have implications for immunotherapy of cancer based on blocking anti-CTLA-4 mAbs.

Citing Articles

Regulation of NK cell development, maturation, and antitumor responses by the nuclear receptor NR2F6.

Woelk J, Hornsteiner F, Aschauer-Wallner S, Stoitzner P, Baier G, Hermann-Kleiter N Cell Death Dis. 2025; 16(1):77.

PMID: 39920136 PMC: 11806049. DOI: 10.1038/s41419-025-07407-4.


The emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer.

Pounds R, Croft W, Pearce H, Hossain T, Singh K, Balega J Front Immunol. 2025; 15():1477781.

PMID: 39835114 PMC: 11743932. DOI: 10.3389/fimmu.2024.1477781.


Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases.

Fife C, Williams J, James F, Gregory S, Andreou T, Sunderland A J Immunother Cancer. 2024; 12(11).

PMID: 39551601 PMC: 11574513. DOI: 10.1136/jitc-2024-009522.


CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.

Peng L, Sferruzza G, Yang L, Zhou L, Chen S Cell Mol Immunol. 2024; 21(10):1089-1108.

PMID: 39134804 PMC: 11442786. DOI: 10.1038/s41423-024-01207-0.


The B7:CD28 family and friends: Unraveling coinhibitory interactions.

Burke K, Chaudhri A, Freeman G, Sharpe A Immunity. 2024; 57(2):223-244.

PMID: 38354702 PMC: 10889489. DOI: 10.1016/j.immuni.2024.01.013.